Design of site-specific protein drugs.
The ability to clone and express proteins at high levels of abundance and purity has led to their increasing consideration as therapeutic agents. The use of various protein engineering and recombinant DNA techniques has enabled progression to where proteins can be tailored so that they have not only the ability to interact with a unique (extra)cellular component in order to produce a pharmacological effect, but their structure can be altered so as to achieve a selective biological disposition. This ability to control the biological dispersion of proteins is becoming a key element in the design of therapeutic polypeptides and proteins, finding application in modalities intended for treating HIV infections, accessible tumor masses, and diseases of the hematopoietic system, etc. For recombinant site-specific systems to be successfully introduced into the clinic, radically different approaches are required during their development and clinical testing. These relate not only to the pharmacokinetics and receptor availability of the drug, but also its pharmacodynamics, its analytics and its safety pharmacology. This contribution examines how the control of the biological disposition of proteins may be achieved using both site-directed mutagenesis, sequence re-ordering, hybrid protein formation, protein resurfacing, as well as synthetic adduction to polymers.
Tomlinson
E
E
Somatix Corporation, Cambridge, MA 02139.
D002872:Chromosome Deletion; D003001:Cloning, Molecular; D015195:Drug Design; D015202:Protein Engineering; D055503:Protein Multimerization; D011506:Proteins / Q000138:chemical synthesis* / Q000235:genetics / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D011506:Proteins; D011994:Recombinant Proteins